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The prevalence of diabetes in the hospital is increasing 
and approximately 18-20% of hospital beds are 
occupied by someone with diabetes [1]. Diabetes dis-
proportionally affects the elderly, with three times 
greater prevalence in hospitalised people aged over 65 
years than in those aged under 45 years [2]. Maintaining 
near normoglycaemia during hospital admissions can be 
very challenging. The impact of the current illness, 
medication changes, alterations to meal timings and 
intake, and requirement for nutrition support in hospital 
can all contribute to sub-optimal glucose control. Both 
hyper- and hypoglycemia in hospital are associated with 
increased risk of complications, length of stay, 
admission to the intensive care unit and mortality [3].  
Attempts to attain target glucose levels with current 
insulin therapy (multiple daily subcutaneous insulin 
injections) titrated according to capillary blood glucose 
measurements can increase the risk of hypoglycemia 
and increase workload for healthcare professionals [4]. 
Older adults are more prone to hypoglycaemia due to 
higher prevalence of comorbidities including poly-
pharmacy, renal and hepatic failure, malnutrition, cog-
nitive impairment and frailty. Additionally, counter-
regulatory mechanisms to hypoglycaemia may be 
attenuated in older adults and symptoms less marked.   
The significant advances in diabetes technologies, 
including subcutaneous insulin pumps and continuous 
glucose monitoring (CGM) systems, over the past 10 
years have led to the development of automated insulin 
delivery (closed-loop) systems. The closed-loop appro-
ach involves communication of real-time glucose data 
provided by a CGM device, to a control algorithm 
(hosted on a smartphone or the insulin pump), which 
then instructs subcutaneous insulin delivery via the 
insulin pump, automatically modifying the insulin 
infusion rate every 5-10 minutes based on the sensor 
glucose levels (Figure 1). One of the key benefits of 
closed-loop glucose control is the automatic and 
continuous modulation of insulin delivery rates to adapt 
to within day and between day variability of exogenous 
insulin requirements. 
Hybrid closed-loop systems require the user to 
manually initiate mealtime insulin boluses, while fully 
closed-loop systems automatically dose insulin without 
information about meals with the advantage of reduced 
user interaction.  
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Hybrid closed-loop systems have been approved by 
regulatory authorities for people with type 1 diabetes 
and are increasingly being used. So far, no closed-loop 
system has been approved for the management of 
inpatient hyperglycaemia but we believe that such 
systems are feasible and may provide substantial 
benefits as described in this editorial.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The feasibility of fully automated closed-loop insulin 
delivery without meal announcement in the inpatient 
setting has been demonstrated to be safe and effective in 
achieving near-normal glucose control [5]. 
A randomised controlled trial involving 136 adults on 
the general wards with hyperglycaemia compared fully 
closed-loop insulin delivery with standard insulin 
therapy for a period of up to 15 days or until discharge 
[6]. The time spent with glucose in the target range 
(100-180 mg/dL) was 66% with closed-loop compared 
with 42% with standard insulin therapy. This 24 
percentage point increase with closed-loop equates to 
almost six additional hours each day with glucose levels 
in target range. This was achieved without any increase 
in hypoglycemia (<54 mg/dL) or in the amount of 
insulin delivered compared to conventional therapy. 
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Figure 1. Closed-loop system. A continuous glucose monitor 
(black device on abdomen) transmits information about 
interstitial glucose levels to a smartphone (in the hand), hosting 
a control algorithm. An insulin pump (in the pocket) delivers a 
rapid-acting insulin analogue subcutaneously. Insulin delivery is 
modulated in real-time by the control algorithm. Communica-
tion between system components is wireless. 
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Closed-loop insulin delivery was associated with 
superior glycaemic control without a higher risk of 
hypoglycemia.  
Determining those most likely to benefit from closed-
loop insulin delivery is critical to support widespread 
adoption of this technology, and demonstrating efficacy 
and safety of closed-loop in the more challenging 
inpatient sub-populations is important for generalisabi-
lity. 
Glucose management in people with diabetes receiving 
hemodialysis can be demanding due to high day to day 
variability in glucose levels and insulin requirements. A 
subgroup analysis of the study by Bally et al. [6] 
examined the impact of fully closed-loop insulin 
delivery in patients undergoing hemodialysis while in 
hospital, compared with standard insulin therapy [7]. 
Those using closed-loop spent significantly more time 
with glucose levels in target range than the control 
group (69% vs 32% respectively), without increasing 
the risk of hypoglycemia. The closed-loop approach 
may offer a novel approach to manage diabetes in this 
vulnerable population and further outpatient studies are 
warranted.  
Administration of nutrition support (enteral/parenteral 
nutrition) in the inpatient setting is associated with 
hyperglycaemia in up to 50% of patients. Management 
of feed-induced hyperglycemia with standard insulin 
therapy can be complex due to unanticipated inter-
ruptions to nutrition support and frequent changes to 
feeding regimens demanding considerable input by 
healthcare professionals. In a randomised controlled 
study involving 43 inpatients receiving nutritional sup-
port, fully automated closed-loop insulin delivery using 
faster-acting insulin aspart was associated with superior 
glucose control compared to standard insulin therapy 
[8]. The closed-loop group spent approximately eight 
additional hours each day with glucose levels in target 
range (100-180 mg/dL) compared with those receiving 
standard insulin therapy (68% v 36%) without an 
increase in hypoglycemia. Fully automated insulin 
delivery is a safe and effective tool to improve 
glycaemic control in hospitalised patients receiving 
nutritional support, where glucose management can be 
particularly challenging. 
The closed-loop approach is an attractive option to 
positively change the management of inpatient diabetes 
particularly in the most challenging inpatient popu-
lations; larger studies are required to determine if the 
observed improved glucose control with closed-loop 
insulin delivery can translate into improved clinical 
outcomes for patients, and reduce staff work burden 
and the healthcare costs associated with inpatient 
diabetes. 
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